ConductScience.org, home

Paper42224880

Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.

Khan RMN and 8 others. J Chromatogr B Analyt Technol Biomed Life Sci, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application. Papers, record 42224880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42224880

Download JSON
Disease
Proteus syndrome1 drug
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.
PubMed
Journal
J Chromatogr B Analyt Technol Biomed Life Sci
PubMed
Year
2026
PubMed
Publication types
Journal Article, Validation Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-22
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Khan RMNR M Naseer
2Arisa OTOluwatobi T
3Zeng YYi
4Rostagni OOlivia
5Redick CCaroline
6Paris KMKathryn M
7Biesecker LGLeslie G
8Ours CAChristopher A
9Figg WDWilliam D

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Liquid Chromatography-Mass SpectrometryMajor topic
Tandem Mass SpectrometryMajor topic
Humans
Chromatography, Liquid
Drug Stability
Limit of Detection
Linear Models
Reproducibility of Results
Aminopyridines
Imidazoles

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZIA CL090115Intramural NIH HHSUnited StatesZIACL090115PubMed

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04316546MK-7075 (Miransertib) in Proteus SyndromeDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127305487Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.J Med Chem2016https://conductscience.org/library/papers/27305487PubMed
220056435Association of paternal age and risk for major congenital anomalies from the National Birth Defects Prevention Study, 1997 to 2004.Ann Epidemiol2010https://conductscience.org/library/papers/20056435PubMed
329240615Enhancement and Suppression of Ionization in Drug Analysis Using HPLC-MS/MS in Support of Therapeutic Drug Monitoring: A Review of Current Knowledge of Its Minimization and Assessment.Ther Drug Monit2018https://conductscience.org/library/papers/29240615PubMed
432014856Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).Cold Spring Harb Mol Case Stud2020https://conductscience.org/library/papers/32014856PubMed
531058421First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.Am J Med Genet A2019https://conductscience.org/library/papers/31058421PubMed
626657992Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.Sci Rep2015https://conductscience.org/library/papers/26657992PubMed
733639990Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.Orphanet J Rare Dis2021https://conductscience.org/library/papers/33639990PubMed
821793738A mosaic activating mutation in AKT1 associated with the Proteus syndrome.N Engl J Med2011https://conductscience.org/library/papers/21793738PubMed
939353238The evolution of small-molecule Akt inhibitors from hit to clinical candidate.Eur J Med Chem2024https://conductscience.org/library/papers/39353238PubMed
1020886116Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.PLoS One2010https://conductscience.org/library/papers/20886116PubMed
1112964746Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.Anal Chem2003https://conductscience.org/library/papers/12964746PubMed
1234858045Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.Pharmgenomics Pers Med2021https://conductscience.org/library/papers/34858045PubMed

Download CSV of references

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AKT2208PubTator's text mininghttps://conductscience.org/library/genes/208NCBI Gene
AKT310000PubTator's text mininghttps://conductscience.org/library/genes/10000NCBI Gene
PIK3CB5291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
MIRANSERTIBCHEMBL4297188Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297188

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Cited by
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42224880

GET https://conductscience.org/api/papers/v1/42224880/authors